Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.(300357),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

300357 Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.

Closed 12-19 15:00:00

29.11

+0.32

+1.11%

High29.59	Low28.79	Vol3.45M
Open28.79	D1 Closing28.79	Amplitude2.78%
Mkt Cap15.25B	Tradable Cap14.09B	Total Shares524.00M
T/O101.00M	T/O Rate0.71%	Tradable Shares484.00M
P/B5.72	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.","latestPrice":29.11,"timestamp":1766127783000,"preClose":28.79,"halted":0,"volume":3453557,"delay":0,"changeRate":0.0111,"floatShares":484000000,"shares":524000000,"eps":0.7457,"marketStatus":"Closed","change":0.32,"latestTime":"12-19 15:00:00","open":28.79,"high":29.59,"low":28.79,"amount":101000000,"amplitude":0.0278,"askPrice":29.12,"askSize":44,"bidPrice":29.11,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.7457,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":28.79,"symbolType":"stock","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":31.67,"lowLimit":25.91,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"isCdr":false,"pbRate":5.72,"roa":"--","peRate":39.037146,"roe":"13.8%","epsLYR":0.607,"committee":0.232274,"marketValue":15242000000,"turnoverRate":0.0071,"status":0,"floatMarketCap":14091000000},"requestUrl":"/m/hq/s/300357","defaultTab":"news","newsList":[{"id":"1164878873","title":"Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) Terminates Aspergillus Fumigatus Skin Prick Test Solution R&D Project","url":"https://stock-news.laohu8.com/highlight/detail?id=1164878873","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164878873?lang=en_us&edition=fundamental","pubTime":"2025-11-14 16:48","pubTimestamp":1763110104,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (300357.SZ) announced that after careful evaluation by the management team, the company has decided to terminate the R&D project for Aspergillus Fumigatus...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300357","BK0028"],"gpt_icon":0},{"id":"1176592717","title":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) Reports Q3 Results with Net Profit of 345 Million Yuan, Up 26.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176592717","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176592717?lang=en_us&edition=fundamental","pubTime":"2025-10-23 19:44","pubTimestamp":1761219855,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) has released its Q3 report for 2025, indicating that the company achieved a revenue of 853 million yuan in the first three quarters, marking a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2570098982","title":"Wolwo Bio-Pharmaceutical Says 'Certain Percentage' of Trial Participants for Fungal Drug Showed Delayed Response in Phase 1 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2570098982","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570098982?lang=en_us&edition=fundamental","pubTime":"2025-09-25 17:47","pubTimestamp":1758793659,"startTime":"0","endTime":"0","summary":"A \"certain percentage\" of participants in Zhejiang Wolwo Bio-Pharmaceutical's (SHE:300357) phase 1 clinical trial for its Aspergillus fumigatus prick solution showed a delayed reaction to the drug, ac","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","300357","BK0028"],"gpt_icon":0},{"id":"1115065919","title":"Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) Receives Phase I Clinical Trial Summary Report for Aspergillus fumigatus Prick Test Solution","url":"https://stock-news.laohu8.com/highlight/detail?id=1115065919","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115065919?lang=en_us&edition=fundamental","pubTime":"2025-09-25 16:34","pubTimestamp":1758789261,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. (300357.SZ) announced that its self-developed \"Aspergillus fumigatus prick test solution\" has completed a clinical study titled \"A Clinical Study Exploring...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","300357","BK0028"],"gpt_icon":0},{"id":"1195402907","title":"Zhejiang Wolwo Bio-Pharmaceutical Releases Semi-Annual Report with 18.61% Net Profit Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1195402907","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195402907?lang=en_us&edition=fundamental","pubTime":"2025-08-21 19:22","pubTimestamp":1755775373,"startTime":"0","endTime":"0","summary":"On August 21st, Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd. released its semi-annual report. According to the announcement, the company's semi-annual operating revenue reached 484,236,510.36 yuan,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0239","300357"],"gpt_icon":0},{"id":"2558365605","title":"Zhejiang Wolwo Bio-Pharmaceutical Enrols First Patient for Patch Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2558365605","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558365605?lang=en_us&edition=fundamental","pubTime":"2025-08-11 18:13","pubTimestamp":1754907218,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical  enrolled the first patient for its dermatitis diagnostic Patch 02 in a phase one clinical trial at Jining First People's Hospital.The study aims to assess the patch's safety in diagnosing allergic contact dermatitis linked to cassone, para-phenylenediamine and formaldehyde, according to a Monday filing with the Shenzhen bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0239","300357"],"gpt_icon":0},{"id":"1153684097","title":"Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ) Projects Robust H1 Profit Growth: Net Attributable Income Forecast at RMB 170M-185M, Surging 13.92%-23.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153684097","media":"Market Watcher","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153684097?lang=en_us&edition=fundamental","pubTime":"2025-07-15 22:06","pubTimestamp":1752588371,"startTime":"0","endTime":"0","summary":"Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) has unveiled its preliminary financial projections for the first half of 2025, signaling a robust earnings trajectory. The biopharmaceutical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","300357","BK0239"],"gpt_icon":0},{"id":"1197215258","title":"Wolwo Bio-Pharmaceutical (300357.SZ) Forecasts H1 2025 Profit Growth; Net Attributable Income Expected at 170-185 Million Yuan, Up 13.92%-23.97% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1197215258","media":"Stock Track","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197215258?lang=en_us&edition=fundamental","pubTime":"2025-07-15 20:08","pubTimestamp":1752581335,"startTime":"0","endTime":"0","summary":"Wolwo Bio-Pharmaceutical (300357.SZ) has released its preliminary earnings guidance for the first half of 2025. The company projects net profit attributable to shareholders to reach between 170...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BK0239","BK0028","300357"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","stockEarnings":[{"period":"1week","weight":-0.0293},{"period":"1month","weight":-0.0779},{"period":"3month","weight":0.0129},{"period":"6month","weight":0.4704},{"period":"1year","weight":0.3663},{"period":"ytd","weight":0.4484}],"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","perCapita":"14927股","boardName":"医药制造业","registeredCapital":"52358万元","compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":-0.0143},{"period":"3month","weight":0.0184},{"period":"6month","weight":0.1579},{"period":"1year","weight":0.1544},{"period":"ytd","weight":0.1607}],"survey":"　　浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂（国药准字S20060012，商品名：畅迪）、黄花蒿花粉变应原舌下滴剂（国药准字S20210001，商品名：畅皓）、以及粉尘螨皮肤点刺诊断试剂盒（国药准字S20080010，商品名：畅点）。","serverTime":1766239092235,"listedPrice":20.05,"stockholders":"32427人(较上一季度减少6.22%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.(300357),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.(300357) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.,300357,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票老虎,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票老虎国际,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.行情,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票行情,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股价,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股市,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票价格,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票交易,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票购买,Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.(300357),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zhejiang Wolwo Bio-Pharmaceutical Co.,Ltd.(300357) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction